2020 ESMO Update on Advanced EGFR-Mutated NSCLC: Mobocertinib (TAK-788), HER3-Directed ADC Patritumab Deruxtecan, EGFR-MET Bispecific Antibody Amivantamab + Lazertinib (3rd Gen TKI)

364 views
November 26, 2020
Courtesy of Lung Cancer Europe (LuCE). The full video can be found here: https://www.lungcancereurope.eu/2020/10/16/luce-webinar-esmo-2020-lung-cancer-highlights/
0 Comments
Login to view comments. Click here to Login